Oova LegitScript and Accreditation Status: Is Oova a Legitimate Fertility Hormone Tracker?

What Is Oova, and Why Are Women Asking About Its Legitimacy?

Oova is a New York-based company that sells a reusable at-home hormone monitoring system. You urinate on a test strip, scan it with the Oova mobile app, and receive quantitative readings for four reproductive hormones: luteinizing hormone (LH), progesterone metabolite (PdG, a urine proxy for serum progesterone), follicle-stimulating hormone (FSH), and human chorionic gonadotropin (hCG). The device is aimed primarily at women who are trying to conceive, women with PCOS or irregular cycles, and women in perimenopause who want to track hormonal fluctuations over time.

Women are right to ask hard questions. The fertility-tech market is crowded and largely unregulated at the software level, and several direct-to-consumer hormone testing companies have faced FDA warning letters or consumer complaints in recent years. Asking whether Oova is accredited, whether it holds a LegitScript certification, and whether real users have filed complaints is not excessive skepticism. It is sensible due diligence.

What "Legitimate" Means in This Context

The word "legitimate" covers at least three distinct questions when you are evaluating a health-tech company:

1. Is the device legally authorized by the FDA to make the claims it makes?
2. Does the company hold third-party accreditations such as LegitScript, URAC, or BBB accreditation?
3. Do independent clinical data support the accuracy claims the company makes to consumers?

These are separate questions with separate answers for Oova. The sections below address each one.

Oova's FDA Regulatory Status

Oova's hormone monitor is regulated as a Class II medical device by the U.S. Food and Drug Administration. Class II devices require either a 510(k) premarket notification demonstrating substantial equivalence to a predicate device or, for genuinely novel devices, De Novo classification. Class II does not require the full clinical trial burden of a Class III premarket approval (PMA), but it does require demonstrating that the device meets performance standards.

The FDA's device database (CFDH) allows you to search cleared devices by company name. As of mid-2025, Oova's test-strip reader system appears under FDA records for home-use fertility monitors. The agency classifies over-the-counter ovulation predictors and home-use fertility monitors under 21 CFR Part 870 and related product codes. FDA clearance means the agency reviewed analytical performance data (sensitivity, specificity, precision) submitted by Oova before the device was marketed.

FDA clearance does not mean the FDA has independently verified every accuracy claim Oova makes in its marketing materials. If the company's promotional language goes beyond what the cleared labeling supports, that can constitute a regulatory violation. No public FDA warning letter to Oova was on record as of this article's publication, but you can verify this yourself by searching the FDA Warning Letters database.

What FDA Clearance Does and Does Not Tell You

FDA clearance tells you the device met a regulatory bar for analytical accuracy on the specific hormones it measures. It does not tell you that using this device will help you get pregnant faster, that its algorithms correctly predict your ovulation window, or that quantitative PdG readings accurately reflect whether your luteal phase is adequate. Those are clinical effectiveness questions, and they require separate, prospective data in women.

ACOG notes that LH surge detection by urine OPKs has been the clinical standard for ovulation timing, but the society has not specifically endorsed any proprietary quantitative home monitor system. Women with PCOS in particular should know that false LH surges are common with standard OPKs in this population, as documented in the reproductive endocrinology literature, and whether Oova's quantitative algorithm performs better than standard OPKs in oligo-ovulatory cycles has not been established in a published, peer-reviewed trial.

LegitScript Certification: Does It Apply to Oova?

LegitScript is a third-party certification body that verifies online pharmacies, telehealth platforms that prescribe medications, and certain healthcare merchant categories as compliant with applicable laws and standards. Google, Microsoft, and several payment processors require LegitScript certification before they will allow advertising for prescription drug dispensing and certain controlled-substance telehealth services.

Oova does not dispense prescription drugs. It sells a diagnostic monitoring device and companion app subscription directly to consumers. Because Oova is a device company, LegitScript certification is simply not applicable to its business model in the way it would be to an online pharmacy or a GLP-1 prescribing telehealth clinic. The absence of a LegitScript certification for Oova is therefore not a red flag. It is a category mismatch.

If a WomanRx reader asked whether her GLP-1 telehealth provider or her hormone therapy prescriber holds LegitScript certification, that question would be directly relevant, and you should check it. For a device-only company like Oova, the relevant credential is FDA device clearance, not LegitScript.

What Accreditations Should You Actually Look For?

For a direct-to-consumer diagnostic device company, the accreditations that carry real meaning are:

• FDA 510(k) or De Novo clearance for the device itself (search accessdata.fda.gov)
• CLIA certification if the company runs a laboratory that processes any samples (Oova processes strips locally on your phone, not in a central lab, so CLIA is not directly applicable to the consumer device, though any partner lab would need CLIA certification)
• ISO 13485 quality management certification for medical device manufacturers
• BBB accreditation as a general consumer-trust signal

Oova's BBB Profile and Consumer Complaints

The Better Business Bureau (BBB) maintains profiles on companies based on complaint history, transparency of business practices, and willingness to resolve disputes. As of mid-2025, Oova's BBB profile shows a limited complaint record. The company does not hold BBB Accreditation, which is a paid voluntary program. Non-accreditation is common among smaller startups and does not by itself indicate a problematic company.

Consumer complaints about Oova that appear across platforms (BBB, Trustpilot, Reddit communities such as r/TryingForABaby) tend to cluster around three themes:

1. Device accuracy concerns. Some users report that Oova's LH readings conflict with positive results from standard OPK strips used simultaneously. Quantitative hormone monitors use different assay thresholds than qualitative strips, and both can be correct within their respective reference ranges, but the discordance confuses users.

2. App and subscription billing issues. Several users report difficulty canceling subscriptions or unexpected charges. These are consumer-experience complaints, not regulatory or clinical safety concerns.

3. Customer service response time. This is consistent across many D2C health-tech companies and is worth knowing before you subscribe.

No pattern of serious adverse events attributable to Oova's device has appeared in the FDA MAUDE (Manufacturer and User Facility Device Experience) database as of mid-2025. You can verify this yourself with a MAUDE search.

The WomanRx Legitimacy Framework for D2C Fertility Tech: When evaluating any at-home hormone monitoring company, check four primary sources in order: (1) FDA device database for clearance status, (2) FDA MAUDE for adverse event reports, (3) FDA Warning Letters database for compliance actions, and (4) peer-reviewed publications for independent accuracy validation. BBB and LegitScript are secondary signals that tell you about business practices and pharmacy compliance, respectively. They do not substitute for the four primary checks above.

Clinical Accuracy: What the Data Actually Show

Oova has published or presented data on its device's analytical performance. The company's internal validation work shows correlation between Oova PdG readings and reference-lab serum progesterone measurements. An accuracy study published in a peer-reviewed journal would carry more weight than company-sponsored validation, and this is an area where independent replication is thin.

ASRM's Practice Committee has noted that confirming ovulation with a serum progesterone level drawn 7 days after the LH surge remains the clinical standard, not a urine PdG surrogate. Urine PdG correlates with serum progesterone but the relationship is not perfectly linear across all women and all phases of the cycle, particularly in women with kidney disease or highly variable hydration status. A 2023 analysis in Fertility and Sterility examined urine hormone monitoring in the context of assisted reproduction and noted that quantitative urine LH and PdG monitoring showed promise for reducing blood draws, but called for larger prospective studies before clinical adoption.

For women with PCOS, the evidence gap is especially notable. Approximately 1 in 10 reproductive-age women has PCOS, making it one of the most common endocrine disorders in women. Oligo-ovulation means that cycle-by-cycle hormone patterns are inherently less predictable, and a device calibrated on ovulatory cycles may not perform equivalently in anovulatory cycles. Oova has stated that its algorithm personalizes thresholds to each woman's baseline. Whether that personalization is sufficient for PCOS patients has not been demonstrated in a published clinical trial specific to that population.

How Oova Measures Hormones Across Life Stages

Oova's four-hormone panel is relevant across different reproductive life stages, but the clinical interpretation differs substantially by stage.

Reproductive Years: Trying to Conceive

In the reproductive years, Oova measures LH to detect the pre-ovulatory surge, PdG to confirm ovulation occurred and assess luteal phase adequacy, FSH as a proxy for ovarian reserve (though a single-cycle FSH measurement is a poor substitute for a timed Day 3 FSH with antral follicle count), and hCG to detect early pregnancy. For timing intercourse or intrauterine insemination, LH detection is clinically established. The added value of real-time quantitative PdG monitoring for predicting conception in natural cycles remains under study.

PCOS and Irregular Cycles

Women with PCOS often cycle irregularly or not at all. LH to FSH ratios are frequently elevated in PCOS, which means that baseline LH levels are higher than average and a single elevated LH reading may not represent a true surge. This LH elevation pattern in PCOS is well-documented. Oova's personalized baseline approach is designed to address this, but you should discuss any Oova readings with your reproductive endocrinologist rather than acting on them independently if you have PCOS.

Perimenopause

FSH rises and becomes erratic in perimenopause, often years before the final menstrual period. The Menopause Society (formerly NAMS) notes that FSH testing alone cannot reliably diagnose perimenopause because levels fluctuate cycle to cycle. Some Oova users in their 40s are using the device to track hormonal variability during perimenopause. The device was not designed or validated for this use case, and the clinical utility of cycle-by-cycle FSH tracking in perimenopause via a urine device has not been established. If you are in your 40s with menstrual changes, a discussion with your clinician about serum FSH, estradiol, and anti-Müllerian hormone (AMH) is more diagnostically informative than a urine FSH series.

Postpartum and Lactation

Oova's hCG detection is relevant in the postpartum context for women who want to confirm a new pregnancy. PdG and LH monitoring may resume once cycles return, though breastfeeding-associated prolactin suppression means that ovulation may not return for months. Oova does not dispense any drug, so there is no pharmacological lactation safety concern associated with using the device.

Pregnancy and Contraception Considerations

Because Oova is a diagnostic device and not a drug or prescribing service, there is no teratogen risk, no pregnancy category, and no contraception requirement tied to its use.

The one direct pregnancy-related clinical note is this: Oova's hCG detection is designed to identify early pregnancy signals, but a positive hCG reading on Oova is not a substitute for a serum quantitative beta-hCG drawn by your clinician to confirm a viable intrauterine pregnancy. If you have had a previous ectopic pregnancy, recurrent pregnancy loss, or any IVF transfer, a serum hCG drawn at your clinic is standard of care, not an at-home urine device. ACOG recommends serum hCG monitoring in women at risk of ectopic pregnancy.

Women using Oova for fertility tracking are, by definition, trying to conceive or monitoring hormones. Contraception is not relevant to this device's use case unless a clinician has separately prescribed a teratogenic medication (such as methotrexate for rheumatoid arthritis, or isotretinoin for acne), in which case reliable contraception is required regardless of any fertility monitoring app or device.

Who This Device Is Right For (and Who Should Be Cautious)

Likely to Benefit

• Women in their reproductive years with regular or near-regular cycles who are trying to conceive and want more data than a standard qualitative OPK provides
• Women who have had borderline or unclear OPK results and want a quantitative LH reading
• Women whose clinicians have suggested tracking PdG to assess luteal phase adequacy before prescribing progesterone supplementation
• Women who are data-oriented and want to build a multi-cycle hormone dataset to bring to their reproductive endocrinologist or OB-GYN

Use With Caution

• Women with PCOS: elevated baseline LH may produce confusing readings even with Oova's personalization algorithm
• Women in perimenopause: FSH variability in this life stage is high, and the device was not validated for perimenopausal monitoring
• Women currently undergoing IVF: all monitoring should be done through your clinic's blood-draw protocol; an at-home device does not replace serial serum estradiol, LH, and progesterone checks during a stimulated cycle
• Women with kidney disease: urine hormone concentrations are affected by renal clearance, and PdG correlations with serum progesterone may be less reliable

Not the Right Tool

• Women who need a formal fertility workup: a urine hormone monitor does not replace a hysterosalpingogram (HSG), antral follicle count, semen analysis of a partner, or a full-panel day 3 bloodwork (FSH, LH, estradiol, AMH)
• Women whose primary concern is menopause diagnosis: serum hormone testing through a clinician remains the standard

The Evidence Gap: What We Wish Oova Would Publish

Women deserve a direct statement about what the data do and do not show. Here is the honest picture as of mid-2025.

Oova has internal validation data comparing its urine hormone readings to reference-lab serum values. That data has not been fully published in a peer-reviewed journal with external statistical audit. The company has presented findings at fertility conferences, which carries some weight, but conference abstracts are not peer-reviewed in the same way as published trials.

No randomized controlled trial has compared live birth rates, time-to-pregnancy, or clinical pregnancy rates in women using Oova-guided monitoring versus standard qualitative OPK monitoring. Live birth rate is the gold-standard endpoint in fertility research, and without a trial using this endpoint, any claim that Oova improves conception outcomes is extrapolated, not directly proven.

This is not unique to Oova. The broader category of quantitative home hormone monitors lacks large, independent RCT data. ASRM's 2022 committee opinion on optimizing natural fertility did not endorse any specific commercial monitor over standard OPK testing for timed intercourse.

Women have been historically underrepresented in clinical device trials, and the fertility-tech sector is no exception. Devices designed for women's reproductive health are sometimes brought to market on analytical validation data alone, without clinical outcome data in the populations who will actually use them. Acknowledging this gap is the honest position. It does not mean Oova is ineffective. It means the highest-quality evidence to confirm effectiveness has not yet been published.

How to Verify Oova's Status Yourself

You do not have to take any company's self-reported claims at face value. Here are the four primary checks you can run today:

1. FDA 510(k) / De Novo database. Go to accessdata.fda.gov and search "Oova" to confirm device clearance status and the specific intended use the FDA cleared.

2. FDA MAUDE adverse event database. Search accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm for reports related to Oova's device.

3. FDA Warning Letters database. Search fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters for any compliance actions involving Oova.

4. PubMed. Search pubmed.ncbi.nlm.nih.gov for "Oova" or "quantitative urine progesterone home monitoring" to find any peer-reviewed publications on device accuracy or clinical outcomes.

If you find discrepancies between what those databases show and what Oova claims on its website, that is a meaningful signal.